Applying Intraoperative Insulin Level Monitoring for Tumor Removal in a Patient With Recurrent Pancreatic Multiple Insulinomas  by Chen, Pei-Yin et al.
410 J Formos Med Assoc | 2011 • Vol 110 • No 6
Contents lists available at ScienceDirect
Journal of the Formosan Medical Association
Journal homepage: http://www.jfma-online.com
J Formos Med Assoc 2011;110(6):410–414
Journal of the 
Formosan Medical Association
ISSN 0929 6646
Formosan Medical Association
Taipei, Taiwan
Volume 110 Number 6 June 2011
Perinatal factors and psychiatric disorders
Intracellular defense against HIV
Hypolipidemia and anti-HCV therapy
Drug resistance of tuberculosis in diabetes patients
Case Report
Applying Intraoperative Insulin Level Monitoring 
for Tumor Removal in a Patient With Recurrent
Pancreatic Multiple Insulinomas
Pei-Yin Chen,1 Ta-Jen Wu,1 Horng-Yih Ou,1 Ming-Chi Li,3 Shu-Chun Hu,1 Shih-Ming Huang2*
Pancreatic multiple insulinoma is a very rare dis-
ease. Surgical treatment is challenging, as the local-
ization of the tumor lesion is rather complicated.
We report a case of a 47-year-old woman with re-
current hypoglycemia after distal pancreatectomy
for her insulinoma. Multiple insulinomas were
found in the first pathology report. Follow-up
abdominal computed tomography (CT) did not
show any lesion. One suspected tumor at the pan-
creatic head was found on abdominal magnetic
resonance imaging (MRI), whereas the result of
the intra-arterial calcium stimulation (IACS) test
suggested diffuse β-cell hyperfunction. Using a
quick insulin assay, intraoperative blood insulin
monitoring demonstrated a decrease in insulin
level after the removal of the main tumor during
the second surgery. A 75% subtotal pancreatectomy
was also performed, and the patient is well with
no hypoglycemic attacks or diabetes reported 15
months after the second operation. In addition to
intraoperative sonography and manual palpation,
intraoperative insulin quick assay may be another
useful guide during surgery.
Most insulinomas are small, solitary, benign,
and intrapancreatic. Multiple insulinomas are
common in multiple endocrine neoplasia type 1
(MEN-1), which accounts for approximately 10%
of all patients with insulinoma.1 For recurrent in-
sulinoma, preoperative localization and definite
complete resection during surgery are challenging
issues.
There are many available techniques for local-
ization of the insulinoma, including transab-
dominal ultrasonography, CT, MRI, endoscopic
ultrasonography (EUS), angiography, IACS, so-
matostatin receptor scintigraphy (SRS), positron
emission tomography (PET), intra-operative 
ultrasonography (IOUS) and intra-operative 
palpation.
We present a case that underwent a second
subtotal pancreatectomy for recurrent hypo-
glycemia due to multiple insulinomas. The 
surgery was performed successfully using intra-
operative insulin level monitoring by a new
quick insulin assay (an electrochemiluminescent
immunoassay).
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Case Report
A 47-year-old woman experiencing episodes of
general weakness and hunger sensations for two
months was diagnosed at a regional hospital as
having hyperinsulinemic hypoglycemia according
to Whipple’s Triad. Her insulin level was high
26.4 μIU/mL (reference range: 0–15.6 μIU/mL)
and her plasma glucose level was 32 mg/dL. An
abdominal CT scan revealed a 1.1-cm nodule at
the tail of her pancreas, so distal pancreatectomy
was performed following the diagnosis of insuli-
noma. Pathology findings revealed multiple pan-
creatic macro and micro endocrine tumors. The
largest tumor measured 1.7 cm, and stained posi-
tive for cytokeratin, chromogranin A and synapto-
physin. Ductulo-insular complexes were also found
(Figure 1). Hypoglycemic symptoms diminished
for three weeks postoperatively, but worsened
again. The patient ate every 3–4 hours to relieve
the symptoms of hunger. Cold sweating, general
weakness, and lethargy were also noted. She was 
transferred to our hospital for further management.
Recurrent hyperinsulinemic hypoglycemia was
confirmed with the insulin level being 60.7μIU/mL
(reference range: 6.0–27.0 μIU/mL) when the
plasma glucose level was 58 mg/dL, giving an I/G
ratio of 1.05. MEN-1 was ruled out following neg-
ative laboratory test findings and imaging of her
pituitary and parathyroid glands, and also the
absence of family history. No obvious lesion was
found on the second abdominal CT scan, despite
the hypoglycemia becoming more severe. Thus,
she received an IACS test, which showed highly
elevated plasma insulin levels at the superior
mesenteric artery, and mild elevation at both 
gastro-duodenal, and splenic arteries after calcium
injection, though increments were not greater than
2-fold more than the prestimulation levels (see
Table). This IACS result suggested diffuse β-cell
hyperfunction. A 1.8-cm nodule at the pancreatic
head was found on the following abdominal MRI
(Figure 2), and so the patient underwent a second
surgery. To avoid hypoglycemic episodes, she re-
ceived octreotide initially and then shifted to dia-
zoxide until 36 hours before the operation. During
the operation, we frequently measured blood in-
sulin and glucose level obtained from a central ve-
nous catheter and tested insulin levels by a newly
available quick insulin assay, the electrochemilu-
minescence immunoassay (ECLIA; Roche Elecsys
Insulin; Elecsys 2010 immunoanalyzer; Roche
Diagnostics). We also used a continuous subcuta-
neous glucose monitor (REAL Time Continuous
Glucose Monitoring; Medtronic MiniMed Inc.).
A nodule (1.6 cm) at the pancreatic head was de-
tected under intra-operative ultrasound. Insulin
and glucose levels were obtained before anesthesia,
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Figure 1. Left panel: Histological specimen of pancreas
from the first surgery revealed a cluster of pancreatic islets
with varied size and shape (B, C), the so-called ductuloin-
sular complex, typical of nesidioblastosis. (A: normal islet,
H & E staining, × 20 magnification). Right panel: microade-
noma. (H & E staining, × 100 magnification).
Table. Results of the intra-arterial calcium stimulation test
Insulin 
Time (s)levels obtained
from each vessel (μIU/mL)
–30 0 30 60 90 120 180
Gastro-duodenal artery 237 258 289 304 324 349 296
Hepatic artery 293 318 282 326 296 271 248
Splenic artery 264 322 321 318 380 433 401
Superior mesenteric artery 145 140 143 198 240 251 176
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when the tumor was massaged, before resection
of the tumor and thereafter. A peak insulin level
up to 11.8μIU/mL (reference range: 2.6–24.9μIU/
mL) was obtained when this tumor was massaged,
and the insulin level dropped markedly from
5.47 μIU/mL before anesthesia to 2.42 μIU/mL
within 18 minutes after this tumor was removed
(Figure 3). Although the main tumor was resected
and the insulin level dropped, we were still wor-
ried about the existence of multiple occult micro-
insulinomas or nesidioblastosis, because of the
diffuse β-cell hyperfunction on the IACS test and
her previous pathologic findings of ductuloinsular
complexes. To prevent recurrent hypoglycemia, 
a 75% subtotal pancreatectomy was then per-
formed. Subcutaneous glucose levels increased
from 106 mg/dL before the skin incision to
234 mg/dL during the laparotomy, even though
the intravenous 10% dextrose water infusion was
tapered from 80 mL/hr to 0 mL/hr. The glucose
level was relatively stable following the removal of
the main tumor, until it rose slowly to 285 mg/dL
3 hours later when the patient woke from anes-
thesia (Figure 3).
Like previous pathology findings, the second
set of results also revealed pancreatic multiple in-
sulinomas associated with diffuse nesidioblastosis,
with the biggest tumor being 1.8 cm in size.
The patient recovered well, with no symptoms
of hypoglycemia, diabetes or exocrine problems
after 15 months follow-up. Fasting glucose ranged
from 79 mg/dL to 96 mg/dL, and insulin level
ranged from 2.49 μIU/mL to 2.85 μIU/mL (refer-
ence range: 2.6–24.9 μIU/mL).
Discussion
Preoperative localization of insulinoma is im-
portant in clinical practice. Angiography, once
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Figure 2. A 1.8-cm tumor (arrow) is noted at the pancreatic
head on the abdominal T2-weighted magnetic resonance
imaging.
Figure 3. Subcutaneous glucose level seen on REAL Time Continuous Glucose Monitoring (Medtronic MiniMed Inc.) is
indicated by the black line. The glucose level rose markedly after the skin incision and after the patient woke from anes-
thesia. The glucose level was otherwise maintained relatively stable after the tumor was resected. The dotted line indicated
insulin levels before anesthesia, when the tumor was massaged, before resection of the tumor and thereafter. A peak insulin
level of up to 11.8 μIU/mL was obtained when the tumor was massaged, and the insulin level clearly dropped within 
18 minutes after the tumor was removed.
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considered the “gold standard” for localization
of insulinoma, has been reported with sensitivi-
ties of 29–64%.2 However, the use of angiography
has declined because of improved non-invasive
imaging techniques and the proposal of a more
sensitive method being combined with IACS.
IACS provides better results, especially for occult
insulinomas, and correctly predicts the source of
excessive insulin secretion by up to 96%.3−5
Complication rate using this technique is low
when performed by an experienced operator.
The likelihood of insulinoma detection by im-
aging techniques depends upon the tumor size
and location. Transabdominal ultrasonography,
CT and MRI are the most common noninvasive
modalities, but yield sensitivity rates of only
9.6–61%, 30–66%, and 37–71%, respectively.6
Other special examinations may be invasive, but
provide better results. For EUS, the sensitivity for
detection of lesions in the pancreatic head, body,
and tail is 92.6%, 78.9%, and 40.0%, respec-
tively, and the overall sensitivity and accuracy is
89.5% and 83.7%, respectively. The accuracy de-
pends on the location of the tumor, and is great-
est for tumors in the pancreatic head.7
Functional examinations such as SRS are
mainly used in localizing primary gastroen-
teropancreatic neuroendocrine tumors, but are
less sensitive for insulinomas, because they have
a low density of somatostatin receptors. The sen-
sitivity rates have been reported as 10–17%.5,8
PET is a promising method for detecting insuli-
noma in adults with a sensitivity rate up to 90%
by fluorine-18-l-dihydroxyphenylalanine (18F-
DOPA).9
During an operation, combining intra-operative
ultrasonography and palpation yield a good sensi-
tivity rate, which ranges from 77% to 100%.6,10,11
How to rapidly confirm complete resection of the
tumor during surgery in this situation is a chal-
lenge. An obviously elevated glucose level is a
guide, but yields poor specificity and takes 30–90
minutes after the tumor has been removed. In one
report, plasma glucose increased an average of
32 mg/dL 30 minutes after resection, 68 mg/dL
after 60 minutes, and 91 mg/dL after 90 minutes.10
The sensitivity of hyperglycemic rebound (defined
as a plasma glucose increment of at least 30 mg/dL
after tumor removal) as a marker of complete re-
section of the insulinoma has been reported to
be 40% at 30 minutes and 83% at 60 minutes
after resection.10 However, the accuracy of hyper-
glycemic rebound varies,11 and it is necessary either
to infuse glucose at a constant rate to avoid falsely
elevated glucose levels, or to take the risk of hypo-
glycemia during the operation. A decreasing in-
sulin level below the normal range would seem
to be an expected indicator, but obtaining a result
with a traditional standard assay takes more than
one hour to generate, making it impractical intra-
operatively. This impracticality was removed from
this procedure in 2002, when Carneiro presented
a rapid insulin assay which took only 8 minutes
to obtain insulin levels.11
Though surgical resection remains the treat-
ment of choice for multiple insulinomas, the extent
of pancreatectomy, which can prevent hypo-
glycemia recurrence and avoid further diabetes
or exocrine failure, is still not definite, especially
when these diseases are rare. Most multiple insuli-
nomas are related to MEN-1, but a frequency of
5% without evidence of MEN-1 has been reported
recently.12 Sixty to eighty percent pancreatectomies
were reported in the treatment of cases with adult
noninsulinoma pancreatogenous hypoglycemia
syndrome,13 thus we performed a 75% pancrea-
tectomy at the second surgery. Since the half-life
of serum insulin is 4 minutes, the insulin level
dropped markedly soon after removal of the main
insulinoma. This observation implied that this
quick hormone dynamic change can be used to
guide the surgical approach in the treatment of
insulinoma, especially occult insulinoma.13 This
method can predict the operative outcome and
may help more in the setting of multiple insuli-
nomas.11 Compared with Future Diagnostics used
by Carneiro et al, we use an available quick insulin
assay, ECLIA, which is similarly priced compared
with the routine method. The assay takes only an
18-minute incubation time and a 20 μL sample
volume. We checked the samples retrospectively
with our routine assay by CLIA (IMMULITE 2000
P.Y. Chen, et al
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system, Siemens Medical Solutions Diagnostics),
which takes 70 minutes to generate results, and
noted that there was a good correlation between
these tests (r = 0.99).
The patient took diazoxide for one more
month until 36 hours before surgery. The dura-
tion of hyperglycemic effect is no more than 
8 hours,14 but the elimination half-life is 20–36
hours.14 It is apparent that the drug had not been
completely metabolized, and this might explain
the strikingly lowered insulin levels during the
operation, as compared with those determined
before diazoxide was taken.
Since sporadic multiple insulinomas are very
rare, MEN-1 should be evaluated first when en-
countering this kind of patient. After IACS testing,
nesidioblastosis is another differential diagnosis,
because of the increment of insulin levels at the
superior mesenteric artery, gastro-duodenal ar-
tery, and splenic artery suggestive of diffuse scat-
tered β-cell hyperfunction, such as nesidioblastosis.
Some reported cases with adult-onset nesidioblas-
tosis were related to post-gastric bypass surgery 
if the patient did not have MEN-1. This case did
not have MEN-1 nor previous gastric surgery. Even
though there was mass formation, which is not
characteristic for nesidioblastosis, there were duc-
tuloinsular complexes found on this patient’s
pathological studies, which is the typical presen-
tation for nesidioblastosis. Despite the very rare
prevalence, the appropriate diagnosis for this pa-
tient should be pancreatic multiple insulinomas
with associated diffuse nesidioblastosis.
We present a case with multiple insulinomas
associated with diffuse nesidioblastosis demon-
strating intraoperative insulin level monitoring by
a quick insulin assay in a 75% subtotal pancrea-
tectomy with resection of the head of the main
tumor. This surgical procedure is another practi-
cal method in confirming removal of the tumor
lesion in patients where localization is difficult,
and may help those with multiple insulinomas.
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